Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  MedinCell    MEDCL   FR0004065605

MEDINCELL

(MEDCL)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
6.64(c) 6.58(c) 6.6(c) 6.58(c) 6.58(c) Last
75 500 3 001 121 1 091 Volume
0.00% -0.90% +0.30% -0.30% 0.00% Change
More quotes
Financials (EUR)
Sales 2020 2,88 M
EBIT 2020 -20,1 M
Net income 2020 -22,7 M
Debt 2020 -
Yield 2020 -
Sales 2021 26,6 M
EBIT 2021 -3,44 M
Net income 2021 -6,16 M
Debt 2021 -
Yield 2021 -
P/E ratio 2020 -5,82x
P/E ratio 2021 -21,2x
Capi. / Sales2020 45,9x
Capi. / Sales2021 4,97x
Capitalization 132 M
More Financials
Company
MedinCell is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal... 
Sector
Pharmaceuticals
Calendar
06/16Earnings Release
More about the company
Latest news on MEDINCELL
01/28MEDINCELL : US Pharma Development Veteran Dr. Richard Malamut Joins the Medical ..
PU
01/28MEDINCELL : US Pharma Development Veteran Dr. Richard Malamut Joins the Medical ..
BU
01/27MEDINCELL : Publication of the 2020 Financial Calendar
BU
01/14MEDINCELL : Corporate presentation January 2020
PU
01/13MEDINCELL : provides a portfolio update for J.P. Morgan Healthcare Conference 20..
PU
01/13MEDINCELL : provides a portfolio update for J.P. Morgan Healthcare Conference 20..
BU
2019MEDINCELL : Publication of the activity report and financial information for the..
PU
2019MEDINCELL : to publish its activity report and financial information of the firs..
PU
2019MEDINCELL : Annual results
CO
2019MEDINCELL : Provisional calendar
CO
2018MEDINCELL : Half-year results
CO
More news
News in other languages on MEDINCELL
01/28MEDINCELL : Spécialiste reconnu du développement pharmaceutique aux États-Unis, ..
01/27MEDINCELL : Publication du calendrier financier 2020
01/13MEDINCELL : fait le point sur son portefeuille produits pour la conférence J.P M..
01/09MEDINCELL : Bilan semestriel du contrat de liquidité
2019EN DIRECT DES MARCHES : Orange, Engie, Airbus, Air France, Elior, Google, Nin..
More news
Sector news : Pharmaceuticals - NEC
02/21Marriott Hires Former Merck CIO as Tech Chief
DJ
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/21DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/21ALLERGAN : Form 8.3 -
DJ
02/21ABBVIE : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart MEDINCELL
Duration : Period :
MedinCell Technical Analysis Chart | MEDCL | FR0004065605 | MarketScreener
Technical analysis trends MEDINCELL
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 9,70  €
Last Close Price 6,58  €
Spread / Highest target 47,4%
Spread / Average Target 47,4%
Spread / Lowest Target 47,4%
EPS Revisions
Managers
NameTitle
Christophe Douat Chief Executive Officer
Anh Nguyen Chairman-Supervisory Board
Sébastien Magnat Head-Operations
Jaime Arango Chief Financial Officer
Christophe Roberge Chief Technical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MEDINCELL-4.36%144
JOHNSON & JOHNSON1.71%395 024
ROCHE HOLDING AG10.08%300 195
NOVARTIS2.89%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.50%197 679